AI assistant
Pacira BioSciences, Inc. — Director's Dealing 2021
Aug 5, 2021
32125_dirs_2021-08-05_89451bd1-1af6-49da-b2eb-cb2c0d65981e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Pacira BioSciences, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2021-08-03
Reporting Person: WINSTON ROY (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-03 | Common Stock | A | 5000 | $0.00 | Acquired | 36456 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-08-03 | Stock Option (Right to Buy) | $60.79 | A | 10000 | Acquired | 2031-07-20 | Common Stock (10000) | Direct |
Footnotes
F1: Represents restricted stock units that vest in four equal annual installments beginning on August 1, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2: Includes 421 shares of common stock acquired under the issuer's employee stock purchase plan in June 2021.
F3: The stock option vests and becomes exercisable as to 25% of the option shares on June 20, 2022, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.